title: Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients.
abstract: Psoriatic arthritis (PsA) is a chronic inflammatory condition, characterized by an excess of metabolic disorders. Metabolic syndrome (MetS) is a cluster of classic cardiovascular risk factors, due to an imbalance between pro- and anti-inflammatory adipokines. Tumor necrosis factor (TNF)-α is a pro-inflammatory adipocytokine mainly produced by monocytes and macrophages with a central role in inflammatory responses, but it also induces adipocytes apoptosis, promotes insulin resistance, and stimulates lipolysis. The aim of this study was to evaluate the impact of therapy with etanercept (ETN), adalimumab (ADA), and methotrexate (MTX) on MetS components in a cohort of PsA patients with a follow-up period of 24 months. A retrospective study has been conducted in a cohort of PsA patients. On the basis of the inclusion criteria, we identified the first 70 consecutive patients, respectively, on ADA, ETN, and MTX, for a total of 210 patients achieving PsARC criteria during the observation period. As part of the routine clinical practice, assessment of metabolic parameters and of disease activity was recorded at baseline (T0), at 12 months (T1), and at 24 months (T2). The results show that when the specific components of the MetS were considered, taking also into account by regression analysis the effect of the confounding factors, the patients on etN and ADA show a significant improvement of the metabolic syndrome components (in detail, waist circumference, triglycerides, high-density lipoprotein cholesterol, and glucose) as compared to the MTX group. In conclusion, these data suggest that the biologic treatment in PsA can no longer be taken into consideration only for its positive effect on articular and cutaneous symptoms but also on the various aspects of this complex picture.
authors: Luisa
authors: L
authors: Costa
authors: Francesco
authors: F
authors: Caso
authors: Mariangela
authors: M
authors: Atteno
authors: Antonio
authors: A
authors: Del Puente
authors: Md Abud
authors: MA
authors: Darda
authors: Paolo
authors: P
authors: Caso
authors: Augusta
authors: A
authors: Ortolan
authors: Ugo
authors: U
authors: Fiocco
authors: Roberta
authors: R
authors: Ramonda
authors: Leonardo
authors: L
authors: Punzi
authors: Raffaele
authors: R
authors: Scarpa
mesh_terms: D000068879:Adalimumab; D017667:Adipocytes / Q000166:cytology; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D018501:Antirheumatic Agents / Q000008:administration & dosage; D017209:Apoptosis; D015535:Arthritis, Psoriatic / Q000150:complications / Q000188:drug therapy*; D001688:Biological Products / Q000627:therapeutic use; D015331:Cohort Studies; D015897:Comorbidity; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage*; D007249:Inflammation / Q000378:metabolism; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications / Q000188:drug therapy*; D008727:Methotrexate / Q000008:administration & dosage*; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage*; D012189:Retrospective Studies; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D001688:Biological Products; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab; D000068800:Etanercept; D008727:Methotrexate
references: Ann Rheum Dis. 2010 Jan;69(1):48-53
references: 19147615
references: Clin Rheumatol. 2012 Apr;31(4):711-5
references: 22113824
references: Diabetes Res Clin Pract. 2007 Feb;75(2):235-40
references: 16872712
references: Br J Dermatol. 2007 Dec;157(6):1273-4
references: 17916219
references: Clin Dev Immunol. 2011;2011:352686
references: 21804855
references: Autoimmun Rev. 2011 May;10(7):369-74
references: 21195808
references: Wien Klin Wochenschr. 2002 Dec 30;114(23-24):1004-7
references: 12635469
references: Metab Syndr Relat Disord. 2010 Aug;8(4):331-4
references: 20367239
references: Arthritis Rheum. 2006 Aug;54(8):2665-73
references: 16871531
references: J Rheumatol. 2008 Jul;35(7):1434-7
references: 18609740
references: Arthritis Care Res (Hoboken). 2011 Feb;63(2):195-202
references: 20890981
references: J Rheumatol. 2006 Dec;33(12):2440-6
references: 17014005
references: Lancet. 2005 Apr 16-22;365(9468):1415-28
references: 15836891
references: Autoimmun Rev. 2007 Sep;6(8):524-8
references: 17854743
references: Rheumatology (Oxford). 2012 Dec;51(12):2215-23
references: 22923754
references: Autoimmun Rev. 2010 Oct;9(12):849-52
references: 20692379
references: Autoimmun Rev. 2009 Jun;8(7):538-42
references: 19189867
references: Curr Rheumatol Rep. 2012 Aug;14(4):343-8
references: 22562431
references: Autoimmun Rev. 2009 Mar;8(5):415-9
references: 19168158
references: Ann Rheum Dis. 2013 Dec;72(12):1956-61
references: 23243196
references: Ann Rheum Dis. 2000 Nov;59(11):904-9
references: 11053070
references: Clin Exp Rheumatol. 2009 Jan-Feb;27(1):79-83
references: 19327233
references: Int J Rheumatol. 2012;2012:714321
references: 22645614
references: Diabetes Care. 2006 Jul;29(7):1712-3
references: 16801612
references: J Rheumatol. 2012 Feb;39(2):437-40
references: 22298276
references: Semin Arthritis Rheum. 1973;3(1):55-78
references: 4581554
references: Autoimmun Rev. 2003 Oct;2(6):346-57
references: 14550876
references: Semin Cell Dev Biol. 1999 Feb;10(1):19-29
references: 10355025
references: Autoimmun Rev. 2011 Aug;10(10):582-9
references: 21539940
references: Rheumatology (Oxford). 2008 May;47(5):718-23
references: 18400833
references: Br J Nutr. 2004 Sep;92(3):347-55
references: 15469638
references: Arthritis Care Res (Hoboken). 2010 Jul;62(7):965-9
references: 20589696
references: Autoimmun Rev. 2011 Oct;10(12):773-8
references: 21684355
references: J Eur Acad Dermatol Venereol. 2010 Jun;24(6):627-30
references: 20202053
references: JAMA. 2001 May 16;285(19):2486-97
references: 11368702
references: Ann Rheum Dis. 2002 Apr;61(4):298-304
references: 11874829
references: Autoimmun Rev. 2011 Aug;10(10):631-5
references: 21539939